Psychemedics Corporation (PMDI)
PNK · Healthcare · Diagnostics & Research
Closing price as of 2026-07-28 · Source: TEK2day Finance
Key Metrics
About Psychemedics Corporation
Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. The company provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising aka K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for job applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Dallas, Texas.
Quarterly Financials
| Metric | 2024-09-30 | 2024-12-31 |
|---|---|---|
| Revenue | 5.2M | 4.4M |
| Gross Profit | 2.0M | 1.4M |
| Operating Income | -595K | 168K |
| Net Income | -535K | 189K |
| Diluted EPS | $-0.09 | $nan |
Annual Financials
| Metric | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue | 24.9M | 25.2M | 22.1M | 19.7M |
| Gross Profit | 10.3M | 9.3M | 8.4M | 7.1M |
| Operating Income | 209K | -1.1M | -2.9M | -1.9M |
| Net Income | -665K | -1.1M | -4.2M | -1.9M |
| Diluted EPS | $-0.12 | $-0.19 | $-0.72 | $nan |